These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20030467)

  • 1. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.
    Cavallari LH; Groo VL; Viana MA; Dai Y; Patel SR; Stamos TD
    Pharmacotherapy; 2010 Jan; 30(1):1-9. PubMed ID: 20030467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race influences the safety and efficacy of spironolactone in severe heart failure.
    Vardeny O; Cavallari LH; Claggett B; Desai AS; Anand I; Rossignol P; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2013 Sep; 6(5):970-6. PubMed ID: 23940307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial differences in potassium response to spironolactone in heart failure.
    Cavallari LH; Groo VL; Momary KM; Fontana D; Viana MA; Vaitkus P
    Congest Heart Fail; 2006; 12(4):200-5. PubMed ID: 16894278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.
    Hu Y; Carpenter JP; Cheung AT
    Anesth Analg; 2002 Jul; 95(1):39-41, table of contents. PubMed ID: 12088939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
    Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
    J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is spironolactone safe for dialysis patients?
    Hussain S; Dreyfus DE; Marcus RJ; Biederman RW; McGill RL
    Nephrol Dial Transplant; 2003 Nov; 18(11):2364-8. PubMed ID: 14551367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperkalemia during spironolactone use in patients with decompensated heart failure.
    Lima MV; Ochiai ME; Cardoso JN; Morgado PC; Munhoz RT; Barretto AC
    Arq Bras Cardiol; 2008 Sep; 91(3):177-82, 194-9. PubMed ID: 18853060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.
    Squire IB; Gabrielsen A; Greasley PJ; Wernevik L; Hartleib-Geschwindner J; Holden J; Johansson S; Rudvik A; Sánchez J; Bamberg K; Melin J; Whittaker A
    Clin Transl Sci; 2022 Oct; 15(10):2493-2504. PubMed ID: 35971596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
    Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
    J Card Fail; 2004 Aug; 10(4):297-303. PubMed ID: 15309695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aldosterone and its antagonists in heart failure].
    Lopes ME; Le Corvoisier P; Tabet JY; Su JB; Badoual T; Cachin JC; Merlet P; Castaigne A; Hittinger L
    Presse Med; 2003 Jan; 32(2):79-87. PubMed ID: 12653034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of spironolactone use in ambulatory heart failure patients.
    Lopes RJ; Lourenço AP; Mascarenhas J; Azevedo A; Bettencourt P
    Clin Cardiol; 2008 Nov; 31(11):509-13. PubMed ID: 19006114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
    Pitt B; Anker SD; Bushinsky DA; Kitzman DW; Zannad F; Huang IZ;
    Eur Heart J; 2011 Apr; 32(7):820-8. PubMed ID: 21208974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
    Butler J; Hernandez AF; Anstrom KJ; Kalogeropoulos A; Redfield MM; Konstam MA; Tang WH; Felker GM; Shah MR; Braunwald E
    JACC Heart Fail; 2016 Sep; 4(9):726-35. PubMed ID: 27522631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
    Berry C; McMurray JJ
    Heart; 2001 Apr; 85(4):E8. PubMed ID: 11250985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.